<DOC>
	<DOCNO>NCT02254941</DOCNO>
	<brief_summary>The purpose study evaluate , term overall survival , benefit monoclonal antibody start time diagnosis advance disease administer defer basis progression treatment chemotherapy alone .</brief_summary>
	<brief_title>Observational Study Evaluate Use Targeted Therapies Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients diagnose metastatic colorectal cancer biopsy positive adenocarcinoma . ECOG PS02 . Who receive prior chemotherapy treatment metastatic disease . Measurable evaluable disease . No previous surgery metastatic disease . Surgery metastasis allow inclusion study aftercare discretion investigadors . Chemotherapy treatment doublet ( CAPOX , FOLFOX , FOLFIRI ) Patients old 70 year frailty criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Metastatic Colon Cancer</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>First line</keyword>
</DOC>